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ABSTRACT
Alternative splicing of competing 50 splice sites is
regulated by enhancers and silencers in the spliced
exon. We have characterized sequences and
splicing factors that regulate alternative splicing of
PLP and DM20, myelin proteins produced by
oligodendrocytes (OLs) by selection of 50 splice
sites in exon 3. We identify a G-rich enhancer (M2) of
DM20 50 splice site in exon 3B and show that
individual G triplets forming M2 are functionally
distinct and the distal group plays a dominant role.
G-rich M2 and a G-rich splicing enhancer (ISE) in
intron 3 share similarities in function and protein
binding. The G-rich sequences are necessary for
binding of hnRNPs to both enhancers. Reduction in
hnRNPH and F expression in differentiated OLs
correlates temporally with increased PLP/DM20
ratio. Knock down of hnRNPH increased PLP/
DM20 ratio, while hnRNPF did not. Silencing
hnRNPH and F increased the PLP/DM20 ratio more
than hnRNPH alone, demonstrating a novel syner-
gistic effect. Mutation of M2, but not ISE reduced
the synergistic effect. Replacement of M2 and all
G runs in exon 3B abolished it almost completely.
We conclude that developmental changes in
hnRNPH/F associated with OLs differentiation
synergistically regulate PLP alternative splicing
and a G-rich enhancer participates in the regulation.
INTRODUCTION
Alternative RNA splicing of a single gene transcript is a
common strategy to generate multiple protein isoforms
with diﬀerent functional properties (1). A type of
alternative splicing is the inclusion/exclusion of exon
between competing 50 splice sites (2). The regulation of
this type of alternative splicing has been shown to be quite
complex in genes expressed in a variety of tissues and in
artiﬁcial chimeric genes (3,4). In the central nervous
system (CNS), much of the transcript and protein
complexity is generated by alternative splicing, which is
regulated in a cell- and development-speciﬁc manner (5,6).
Proteolipid protein (PLP), a major CNS myelin protein
comprises two protein products, PLP and DM20, which
are generated by alternative splicing of two competing
50 donor sites resulting in either inclusion or exclusion of
exon 3B (7).
In oligodendrocytes (OLs), the myelin-producing cells
of the CNS, the PLP 50 splice site is preferentially utilized,
while in OLs progenitor cells (OPCs) and in other cell
types, DM20 is the preferred site (8,9). Although DM20 is
the ancestral gene and PLP did not appear until relatively
recently in evolution (10,11), PLP is the more abundant of
the two protein isoforms in the mammalian post-natal
brain and is uniquely expressed in myelin. The inclusion
of exon 3B confers PLP unique signaling functions in
axo-glial interactions that maintain axonal integrity
(12,13). In diﬀerentiated OLs and in the post-natal
brain, the ratio of PLP to DM20 transcripts is 3:1 and
accounts for the preponderance of the PLP protein
isoform. Tight control of the PLP/DM20 ratio is critical
for normal brain development and function. Mutations
that impair the PLP/DM20 ratio cause a spectrum
of developmental and degenerative disorders in humans
(14–16). Thus, the identiﬁcation of regulatory sequences
and factors that control the PLP/DM20 ratio is of critical
importance for the understanding of brain development
and human disease and may also provide insight into the
evolutionary history of alternative splicing.
A PLP splicing construct, in which the alternative
inclusion of PLP exon 3B is reconstituted was used to
characterize the eﬀect of disease-causing mutations on
exon 3B splicing (14–16). An analysis of mutations at and
around the PLP and DM20 splice site showed that the
intrinsic strength of the competing 50 splice sites
contributes to the ﬁnal PLP/DM20 ratio (14). Although
the DM20 50 site is weaker than the PLP 50 site (14), it is
the preferred site in OPCs and non-glial cells, suggesting
that either an enhancer of DM20 or a silencer of PLP
50 splice site may regulate PLP alternative splicing in these
cells. Analysis of mutations occurring in patients have
identiﬁed enhancers of PLP 50 splice site: a G-rich intronic
splicing enhancer (ISE) (15) and an exonic splicing
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(16). In other genes, the exon between competing 50 splice
sites has been shown to contain enhancers and silencers
that regulate the alternative splicing selection (4,17–19).
In this study, we investigate the role of regulatory
sequences in PLP exon 3B by systematically mutating
exon 3B. We characterize a novel G-rich enhancer of
DM20 50 splice site and its relationship with a G-rich
ISE of PLP 50 splice selection using functional and
biochemical approaches. The hnRNP H and F bind to
both enhancers. A reduction in the hnRNPH/F expression
levels correlates temporally with the inclusion of PLP exon
3B in diﬀerentiated OLs. We investigate the role of
hnRNPH and F in the regulation of PLP/DM20 ratio by
knocking down their expression. This study deﬁnes a
novel synergistic regulation of PLP/DM20 mediated by
hnRNPH and F and establishes a role of a novel G-rich
enhancer in PLP alternative splicing.
MATERIALS AND METHODS
Cell cultures and transfections
Immunoselected OPCs were cultured in B104-conditioned
medium and diﬀerentiated into OLs in T3 medium
(40ng/ml) for 72h (16,20). Oli-neu cells (kind gift of
Dr Trotter) were cultured in SATO medium with 1%
horse serum and diﬀerentiated in dbcAMP, 1mM for
3–10 days (21). L cells were grown in DMEM containing
10% FBS. OPCs plated at 7 10
5 cells/well, Oli-neu cells
at 5 10
5 cells/well and L cells at 3 10
5 cells/well were
transfected for 6h with 0.5mg plasmid DNA using Qiagen
Eﬀectene Transfection Reagents (Qiagen, Valencia, CA,
USA). After 18h in growth medium, the cells were
cultured in diﬀerentiation medium and harvested 72h
after transfection.
Plasmid constructs
Mutant PLP-neo constructs were generated by site-
directed mutagenesis using the QuikChange Site-
Directed Mutagenesis Kit and the QuikChange Multi
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA) (Figures 1–5).
siRNA and Western blot
Pre-designed double-stranded (ds) siRNAs targeting
hnRNPF [175720 (siF1), 175721 (siF2) and 175722
(siF3); H [182015 (siH1), 182016 (siH2) and 75775
(siH3)], a custom-made ds siRNA, siF/H [target
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Figure 1. PLP-neo construct and mutations in PLP exon 3B. (A) Schematic representation of the PLP-neo splicing construct. The arrows indicate the
position of the PCR primers. The PLP and DM20 PCR products are shown. (B) Exon 3B: 349 indicates G at the invariant GT of DM20 50 splice
site, 453 is the last base of exon 3B at the PLP 50 splice site, 409 is the position of a human mutation occurring in an ASF/SF2 motif and ESE
indicates the ASF/SF2 binding motif (16). The linker scan sequence substitutions are aligned below the wild-type sequences. All mutant constructs
replace 10nt, except for M6 and M10 (see text), and are of the same length as the wild-type construct.
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524–542nt of mouse hnRNP F cDNA (Accession# NM-
133834), hnRNP H cDNA (Accession# NM-021510)] and
Silencer Negative Control #1 siRNA were purchased
from Ambion (Austin, TX, USA).
Undiﬀerentiated Oli-neu cells were transfected with
siRNA (50–100nM) alone or in combination with
reporter plasmids (0.5 mg) in siPORT amine transfection
reagent using the neofection protocol (Ambion, Austin,
TX, USA). To keep constant the amount of siRNA,
Silencer Negative Control #1 siRNA was added to
transfections in which a single siRNA was used. Western
blots of cell lysates (10mg proteins) were performed using
the One-Step
TM Complete Western Kit (Genescript,
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Figure 2. Mutation of a G-rich sequence activates inclusion of PLP exon 3B. Results of RT-PCR assay of PLP and DM20 from total RNA isolated
from Oli-neu cells (30 PCR cycles) (A) and L cells (35 PCR cycles) (B) transfected with wild-type PLP-neo (WT) and M1-MT to M10-MT. The PLP/
DM20 ratios SD are shown (n=3). GAPDH is used for accuracy of RNA loading (25 PCR cycles). Control represents the untransfected cells.
The increase in PLP/DM20 ratio with the M2-MT construct is statistically signiﬁcant (P=0.017 for Oli-neu cells and P50.002 for L cells).
Figure 3. Analysis of G triplets within M2 in Oli-neu cells and primary oligodendrocytes. (A) Partial wild-type sequences of exon 3B are shown and
M2 is underlined. Linker scan mutations of M2 and G triplets within M2 are shown. (B) Results of RT-PCR assay of PLP and DM20 from RNA
isolated from diﬀerentiated Oli-neu cells transfected with wild-type PLP-neo (WT) and mutated constructs, M2-MT, M2-MT2, G2-MT, G3-MT and
G2-G3-MT. The PLP/DM20 ratios SD are shown (n=3). The upper and lower limits of accurate quantiﬁcation of the PLP/DM20 ratio are
10 and 0.01. (C) PLP and DM20 PCR products ampliﬁed in RNA extracted from diﬀerentiated OLs transfected with WT and M2-MT, M2-MT2
and G3-MT, duplicate transfections are shown.
4166 Nucleic Acids Research, 2007, Vol. 35, No. 12Piscataway, NJ, USA). Blots were probed with 10mg
primary antibody to hnRNP F [rabbit polyclonal,
generous gift of Dr Milcarek, (22,23)] and hnRNP H
(Bethyl Laboratories). Bands were quantitated with
Kodak 440CF Digital Image station using 1D analysis
software with actin as a standard for loading.
RNA extraction and RT-PCR
Total RNA was extracted with RNeasy Mini Kit (Qiagen,
Valencia, CA, USA) and treated with the DNA-free Kit
(Ambion, Austin, TX, USA). Total RNA (0.5mg) was
reverse transcribed using random hexamer primers (BD
Biosciences, Palo Alto, CA, USA). The PLP and DM20
PCR products and PLP+DM20 product derived from
PLP-neo were ampliﬁed and quantitated as described (16)
(Figures 1A and 4A).
Nuclear extracts and Western blot analysis
Nine micrograms of proteins of nuclear extracts (NEP,
Pierce) were separated by 10% SDS-PAGE, blotted
and reacted with MAb104 (ATCC), antibodies to
b-tubulin (Sigma, T 4026), PCNA (Santa Cruz),
hnRNPH and F [rabbit polyclonal, generous gift of
Dr Milcarek, (22,23)], A1 (MAb9H10, generous gift of
Dr Dreyfuss) and L (AbCam) diluted 1:2000 and QKI5
(Bethyl Laboratories) diluted 1:1000, HRP-conjugated
secondary antibody (Jackson ImmunoResearch
Laboratories) diluted 1:5000 and developed with
enhanced chemiluminescence (ECL, Amersham) (16).
Blots were quantiﬁed with Kodak 440CF Digital Image
Station using 1D analysis software with tubulin as a
standard for loading and quantiﬁcation.
Figure 4. M2 is an enhancer of DM20 50 splice site selection. (A) PLP-neo construct and primers used for PCR ampliﬁcation. Partial sequences of the
natural exon 3B (WT) and mutated constructs are shown, underlined are mutations at the DM20 and PLP 50 splice site and the M2-MT. (B) PLP
and DM20 PCR products (35 PCR cycles) from WT and DM20G4T and DM20G4T-M2-MT ampliﬁed with primers 1 and 2 in RNA extracted
from transfected Oli-neu cells. (C) PLP and DM20 PCR products (35 PCR cycles) derived from WT, c.453+2T4C and c.453T4C-M2-MT ampliﬁed
with primers 1 and 2 in RNA extracted from Oli-neu cells. Plasmid-derived PLP+DM20 PCR product was ampliﬁed with primers 3 and 4 and
represents the total plasmid-derived PLP/DM20 transcript. Endogenous PLP+DM20 PCR product ampliﬁed with primers 1 and 4 is the control for
RNA loading.
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Biotinylated RNA oligonucleotides (500pmol) (Integrated
DNA Technologies, Inc) were incubated with 200mg
proteins of nuclear extracts in buﬀer containing 4mM
creatine, 2mM ATP, 1.5mMMgCl2, 1.2mM DTT for
20min at 308C, heparin was added and the reactions were
exposed to 254nmUV light with a Spectronics XL-1000
UV crosslinker at a setting of 1.8J/cm
2 on ice (about
10min). RNA-binding proteins were precipitated with
streptavidin beads (Pierce, Rockford, IL, USA). Fifty
microliters of prewashed immobilized streptavidin beads,
800ml binding buﬀer and 10ml Halt Protease Inhibitor
Cocktail (Pierce, Rockford, IL, USA) were added to the
UV-crosslinked reactions, incubated at 48C in a rocking
platform, and washed at least eight times with binding
buﬀer prior to gel electrophoresis. Proteins from half of
the entire mixture were separated by 10% SDS-PAGE and
either visualized by silver staining (Bio-Rad) or detected
by Western blot.
Proteinisolation and identification by liquid
chromatography–mass spectroscopy(LC–MS/MS)
Bands separated in 1D gel stained with silver stain were
excised, destained and digested with trypsin. Samples were
prepared and loaded on the MALDI plates and analyzed
by Qstar XL with the MALDI source (Proteomics and
Mass Spectroscopy Core Facility, University of
Kentucky). The three most abundant peptide ions were
automatically selected to perform MS/MS to obtain
sequence information and help increase the conﬁdence of
a match with a known protein. Measured peptide masses
obtained with MALDI–MS/MS and LC–MS/MS were
compared with peptide masses from an in silico digestion
of the protein database using MASCOT search engine for
protein identiﬁcation and modiﬁcation detection.
RESULTS
PLP exon 3Bcontainssequences that regulate
the PLP/DM20 ratio
To identify novel regulatory sequences that control the
PLP/DM20 ratio, we have systematically mutated
PLP exon 3B in a PLP splicing construct and assessed
in vivo splicing in transfected Oli-neu cells (Figure 1A).
In published work, we transfected primary OLs (14–16).
In the present study, we have used Oli-neu cells,
immortalized OPCs that are induced to diﬀerentiate by
dbcAMP (21,24). Because the eﬃciency of transfection in
Oli-neu cells is 36% compared with 6% in primary OLs
(data not shown), changes in plasmid-derived PLP/DM20
ratio are more easily quantiﬁed. We have validated the use
of Oli-neu cells as a model for the OLs in splicing studies.
We have established that various PLP-neo constructs
previously tested in primary OLs expressed the same PLP
and DM20 products when transfected into Oli-neu cells
(data not shown). Expression results for some of
the critical mutations characterized in the present study
in Oli-neu cells were conﬁrmed in primary OLs (Figure 3).
Finally, we show that diﬀerentiated Oli-neu cells replicate
the trend of changes in hnRNP’s expression that we detect
in diﬀerentiated OLs (Figure 7).
Figure 5. Functional analysis of M2 and ISE. (A) Partial sequences of exon 3B: M2 and ISE (small cases) are underlined. The mutations and
the name of the constructs are shown (see text for details). (B) Results of RT-PCR assay of PLP and DM20 from diﬀerentiated Oli-neu cells
transfected with wild-type PLP-neo (WT) and mutant constructs, M2-MT, ISEdel, M2-MT-ISEdel, ISE-ISE and M2F-M2F. This is a representative
experiment (n=2).
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exon 3B (M1-M10) were replaced by a poly-T linker (25).
In order to not aﬀect sequences that are necessary for
recognition of the 50 splice site by the spliceosome, we
began replacing bases after position +8 relative to the
DM20 50 splice site (349, Figure 1A) up to the fourth base
preceding the PLP 50 splice site (453, Figure 1A) (26).
Ten bases were replaced except for M6 and M10, which
both contain seven base changes. M6 spans an ASF/SF2
binding motif that regulates PLP alternative splicing (16)
(Figure 1B).
Following transfection and expression of PLP-neo
constructs carrying the mutated M1–M10 (M1-MT–
M10-MT) in Oli-neu cells diﬀerentiated in medium
containing dbcAMP for 72h, the PLP and DM20
products were simultaneously ampliﬁed by RT-PCR
(Figure 2A). Replacement of a G-rich sequence in the
50 end of exon 3B (M2) resulted in 5.4-fold increase in
PLP/DM20 ratio compared with the WT (Figure 2A).
In contrast, replacement of the other exon 3B sequences
caused a reduction in the PLP/DM20 ratio, with
sequences replaced in M1, M8 and M10 having less of
an eﬀect (Figure 2A). Similar changes in the PLP/DM20
ratio were detected in Oli-neu cells transfected with
M1-MT/M10-MT and diﬀerentiated for 6 days (data
not shown).
To determine whether replacing M2 aﬀects the
PLP/DM20 ratio in non-glial cells, we transfected L cells
with M1-MT through M10-MT and quantiﬁed the
plasmid-derived PLP and DM20 products by RT-PCR.
Although the PLP/DM20 ratio is low in L cells consistent
with the cell-speciﬁc regulation of PLP 50 splice site
recognition (16), replacement of M2 resulted in 7.8-fold
increase in the PLP/DM20 ratio, suggesting that M2 is
active in L cells (Figure 2B). To conﬁrm the functional
relevance of M2, we replaced M2 with an IgM sequence
(-GCATGACTCT-) (M2-MT2) (Figure 3A) (27). In M2-
MT2-transfected Oli-neu cells, the PLP/DM20 ratio was
6.4-fold higher than in WT-transfected cells (Figure 3B),
conﬁrming that M2 regulates the PLP/DM20 ratio.
These data show that G-rich exonic sequences (M2)
regulate the PLP/DM20 ratio in favor of the DM20
50 splice site in both glial and non-glial cells, although the
eﬃciency of exon 3B inclusion is greater in Oli-neu cells,
suggesting a contribution of cell-speciﬁc context in the
regulation of the PLP/DM20 ratio. The remainder of exon
3B favors PLP 50 splice site selection. Interestingly, every
substitution appears to aﬀect the PLP/DM20 ratio,
suggesting that multiple regulatory elements may be
present in exon 3B. In support of this interpretation is
the ﬁnding that one of these sequences M6 contains a
previously characterized ASF/SF2 motif (Figure 1B, ESE)
and M6-MT reduces the PLP/DM20 ratio consistent with
results obtained by introducing patients’ mutations at this
ASF/SF2 motif (16).
In an artiﬁcial a-globin minigene construct containing
G triplets downstream of duplicated 50 splice sites, the
G triplet was the basic functional unit (28). To determine
the functional relevance of G triplets within M2, PLP-neo
constructs in which either the G triplets at the 50 end (G2)
or 30 end (G3) or the internal GAG triplet (G2–G3)
were replaced with Ts were transiently expressed in
Oli-neu cells (Figure 3A). The PLP/DM20 ratio was
increased 4-fold by mutation of G2 (G2–MT) and 29-fold
by mutation of G3 (G3-MT) compared with WT
(Figure 3B). In contrast, the PLP/DM20 ratio was greatly
reduced by mutation of G2–G3 (G2–G3-MT) and the
PLP product was not detectable (Figure 3B). The data
suggest that M2 is functionally complex and is composed
of G triplets of diﬀerent strengths separated by a triplet
that has an opposite eﬀect.
We next sought to assess the function of M2 in primary
OLs because these cells more closely replicate the
developmental increase in the endogenous PLP/DM20
ratio observed in vivo (Figure 7A). OPCs were transfected
with WT, M2-MT, M2-MT2 and G3-MT and diﬀeren-
tiated into OLs for 72h. The PLP/DM20 ratio was
9.4-fold higher in M2-MT-transfected OLs than in
WT-transfected OLs and in M2-MT2- and G3-MT-
transfected OLs only the PLP product was ampliﬁed.
The results replicate those obtained with Oli-neu cells
(compare Figure 3B with 3C), however, they also show
that the increase in PLP/DM20 ratio in OLs is greater
than in Oli-neu cells in keeping with the higher degree of
diﬀerentiation reached by OLs versus Oli-neu cells. The
data suggest that diﬀerentiation may aﬀect the eﬃciency
of PLP alternative splicing derived from the construct.
M2 isan enhancer ofDM20 50 splicesite
We next sought to determine whether M2 functions as
a silencer of PLP 50 splice site or an enhancer of DM20
50 splice site. We inactivated the DM20 50 splice site
by changing the invariant G (349 in exon 3B) to a T
(Figure 4A). If M2 suppresses PLP 50 splice site,
inactivating the DM20 50 splice site should not increase
the PLP/DM20 ratio. The G4T change caused a complete
loss of the DM20 product and a corresponding increase in
the PLP product in diﬀerentiated Oli-neu cells
(Figure 4B). When both the G4T and the M2-MT
mutations were introduced in PLP-neo, the results were
similar to those obtained with the G4T mutation alone
(Figure 4B). A PCR product of  100bp, which was
consistently ampliﬁed from the G4T and G4T-M2-MT-
transfected cells (Figure 4B) was sequenced and it is the
spliced product in which exon 3 is completely skipped.
These data suggest that M2 is an enhancer of DM20
50 splice site.
We next inactivated the PLP 50 splice site by mutating
the invariant +2T (c.453+2T4C) in the M2-MT con-
struct. This mutation was identiﬁed in humans and
abolishes the PLP 50 splice site (14). If M2 is an
enhancer of DM20 50 splice site, we would expect to
detect a reduction of the DM20 product derived
from c.453+2T4C-M2-MT compared with the WT
and c.453+2T4C. The DM20 product is greatly reduced
in c.453+2T4C-M2-MT-transfected Oli-neu cells, while it
is ampliﬁed in approximately the same amount in
c.453+2T4C as in WT-transfected Oli-neu (Figure 4C).
No PLP product is detected in either construct. The
plasmid-derived PLP+DM20 PCR product ampliﬁed
with a forward primer in the neo gene and reverse
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c.453+2T4C-M2-MT compared with WT and
c.453+2T4C (Figure 4C). This reduction could be
explained by skipping of exon 3 due to ineﬃcient
recognition of the DM20 50 splice site caused by the
M2-MT or less likely ineﬃcient 30 splice site utilization.
Alternatively, the reduction in the combined PLP+DM20
product may be explained by retention of intron 3
resulting in an unstable transcript. However, PCR
products of the predicted size for exon 3 skipping and
intron 3 retention were not detected. Collectively,
these results support the interpretation that M2 is an
enhancer of DM20 50 splice site.
We next tested the function of M2 in a globin-PLP
construct in which PLP exon 3B and 100nt of intron
3 spanning the G-rich ISE were fused to the b–globin gene
(GloPLP, Supplementary Figure S1A and Supplementary
Data). In transfected Oli-neu cells, the ratio of product
including exon 3B to the product excluding exon 3B was
increased 6.3-fold in Glo-PLPM2-MT compared with
Glo-PLP (Supplementary Figure S1B). The data show
that M2 exerts its function in a minimal construct and
suggest that exon 3B and the ﬁrst 100nt of intron 3 are
suﬃcient to regulate the PLP/DM20 ratio. Collectively,
the data show that M2 is an enhancer of DM20 50 site
selection and its function is replicated in a minimal
PLP-globin construct.
Functional analysis of M2 andISE inthe regulation of
PLP/DM20 ratio
M2 and ISE contain G-rich sequences that have
nearly identical composition, raising the possibility that
a balance between these enhancers regulates PLP/DM20
ratio (Figure 5A). To evaluate their functional relation-
ship, we asked whether M2 and ISE enhance the upstream
50 splice site when they are exchanged. The G-rich core
and ﬂanking sequences of the 19-bp ISE contribute to
the enhancer’s function (15). In order to move the ISE
and not change the distance of G sequences from the
50 splice site, we replaced M2 and the ﬁve bases 50 and four
bases 30 of M2 (19nt, M2F) with the ISE and vice versa.
We have made the following constructs: ISE-ISE,
M2F-M2F and M2-MT/ISEdel (Figure 5A). The
naturally occurring ISE deletion (ISEdel) reduces PLP
50 splice site selection (15). PLP and DM20 PCR products
were ampliﬁed in Oli-neu cells transfected with these
constructs and with PLP-neo, M2-MT and ISEdel
(Figure 5B). The PLP/DM20 ratio derived from ISE-ISE
and M2F-M2F was lower than the ratio derived from
the WT, suggesting that the ISE is a strong enhancer
of DM20 50 splice site and M2F is a weak enhancer of PLP
50 splice site. The PLP/DM20 ratio derived from M2-MT/
ISEdel was increased compared with WT, although it was
not as high as that derived from M2-MT (Figures 5B
and 9C). These data suggest that although the ISE and
M2F can replace each other, they diﬀer in the strength by
which they enhance the 50 splice site when removed from
their natural position.
Biochemical analysis of proteins that bindto M2F and ISE
in Oli-neu extracts
To further examine M2F and ISE, we analyzed proteins
that bind to M2F and ISE in diﬀerentiated Oli-neu
nuclear extracts by RNA-aﬃnity precipitations.
Biotinylated 19bp RNA oligoribonucleotides containing
the M2F and ISE sequences and templates in which the
Gs were replaced by poly-U, M2F-MT and ISE-MT
(Figure 6A) were incubated with nuclear extracts.
A reaction without the oligoribonucleotide was used
as control for non-speciﬁc binding to the matrix.
The UV-crosslinked protein–RNA complexes were
precipitated with streptavidin–agarose beads and the
proteins were separated by 10% SDS-PAGE and visual-
ized by silver staining. Representative RNA-aﬃnity
precipitates (n=2) are shown in Figure 6B.
While a number of protein bands of similar molecular
weights (MWs) in the4100 to 50–55kDa and 45–37kDa
range were detected in both ISE and M2F precipitates,
there were bands uniquely present in either precipitate
(shown by asterisks, Figure 6B). The protein bands
detected in non UV-crosslinked precipitates were
similar in gel mobility and pattern to those detected
in UV-crosslinked precipitates, suggesting that the
diﬀerences in protein bands between ISE and M2F
precipitates are likely to reﬂect real diﬀerences in protein
binding rather than shifts in mobility caused by
UV-crosslinking (n=2, data not shown). The data
suggest that proteins of similar and distinct MWs bind
to M2F and ISE.
In precipitates with the ISE-MT, high MW bands were
absent while protein bands in the  45–37kDa range were
still detected (Figure 6B). In contrast, nearly all protein
bands were not detected in precipitates with M2F-MT
(Figure 6B). The generalized reduction in protein
binding to M2F-MT is not due to ineﬃcient synthesis
and/or amount of the M2F-MT template, since all
RNA templates were quantiﬁed prior to the RNA-aﬃnity
precipitations (data not shown). In addition, the diﬀer-
ences in binding are not due to unequal protein loading to
each reaction. Similar levels of PCNA were detected by
Western blot analysis of each RNA–protein mixture
separated by SDS-PAGE prior to streptavidin-beads
precipitation (Figure 6B, upper panel). These data support
the interpretation that the presence of the G-rich
sequences is necessary for binding of all proteins to
M2F, whereas it is required for binding of some, but not
all proteins to the ISE.
To identify proteins whose binding depends on the
presence of G-rich sequences, we have analyzed the
aﬃnity-precipitated proteins by Western blot with
antibodies to known RNA binding proteins. On the
basis of MW, binding motifs in the G-rich sequences, and
published data on proteins binding to G-rich elements
(18,29,30), we anticipated that proteins in the MW range
37–65kDa were likely to be hnRNPs. The RNA-aﬃnity
precipitates were separated by SDS-PAGE, blotted
and probed with antibodies to hnRNPs. The hnRNPA1,
H, F and L were detected in the precipitates with M2F
and ISE, but were not detected in precipitates with
4170 Nucleic Acids Research, 2007, Vol. 35, No. 12M2F-MT and ISE-MT (Figure 6C). While very strong
binding motifs are present in M2F and ISE, only partial
motifs for hnRNPL are identiﬁed. To test the speciﬁcity of
the RNA aﬃnity precipitations, we have probed Western
blots of the RNA aﬃnity precipitates with an antibody
to QKI5, an RNA binding protein that contains a
heterogeneous nuclear ribonucleoprotein K homology
(KH) domain (31) and is not expected to bind to M2F
and ISE and an antibody to PCNA, an unrelated nuclear
protein. We found that both QKI5 and PCNA do not
bind to either the wild-type or mutated RNA templates
(Figure 6C). These data demonstrate the speciﬁcity of the
RNA aﬃnity assay.
We next demonstrated that hnRNPH, F and A1 are
present in the RNA–protein complexes by LC/MS/MS of
three discrete bands in the 37–65kDa MW range of the
ISE precipitates. The peptide sequence data were matched
with the protein database and conﬁrmed to be hnRNPF,
H and A1 (block arrows, Figure 6B). The results
demonstrate that hnRNPs bind to the ISE and M2F in
G sequence-dependent manner and suggest that these
factors may participate in the enhancer’s function.
Westernblot analysis revealsdifferences in expression levels
ofhnRNPs inOLs compared withOPC
We next investigated whether hnRNP A1, H, F and L are
diﬀerentially expressed in OLs versus OPC by Western
blot analysis of nuclear extracts prepared from OPC and
OLs diﬀerentiated for 72h using antibodies speciﬁc for
these hnRNPs (Figure 7B). Signiﬁcant reductions in
hnRNP F (47%), hnRNPH (45%) and hnRNPA1
(37%) levels were detected in OLs compared with OPC
extracts (n=5) (Figure 7B). No change in the hnRNPL
level was detected (Figure 7B). Expression of the SR
proteins detected with the MAb104 antibody did not
change in OLs versus OPC (data not shown) and is in
keeping with previous expression studies of ASF/SF2 in
OLs (16). CNPase, a marker of OLs diﬀerentiation was
expressed in cytoplasmic extracts of OLs, but not in OPC,
indicating that the cells have diﬀerentiated (Figure 7B).
Figure 6. Biochemical analysis of proteins that bind to M2F and ISE in Oli-neu extracts. (A) RNA templates used in RNA aﬃnity precipitations.
The natural G-rich sequences and the mutated poly-U sequences are underlined. (B) Upper panel: Western blot analysis of PCNA levels in each
RNA aﬃnity precipitate. One-tenth of each RNA/protein mixture prior to streptavidin beads precipitation was separated by SDS-PAGE and probed
with an antibody to PCNA. Lower panel: representative silver stained gel of RNA aﬃnity precipitates with biotinylated RNA templates containing
wild-type (M2F and ISE), poly-U (M2F-MT and ISE-MT) and Oli-neu extracts (n=2) (see Materials and Methods section). Controls are
precipitates without nuclear extracts (no NE) and without RNA template (no RNA). The asterisks indicate protein bands that are uniquely present in
precipitates with either M2F or ISE. The block arrows indicate the protein bands that were analyzed by LC/MS/MS and their identity is shown.
(C). Western blot analysis of hnRNPA1, F, H and L in the RNA aﬃnity precipitates (see Materials and Methods Section). Precipitates without
nuclear extracts (no NE) and without RNA template (no RNA) are used as controls. Western blot of Oli-neu and HeLa nuclear extracts (9 mg) were
used as control for the reactivity of the antibody. PCNA and QKI5 antibodies, used as control of the speciﬁcity of RNA aﬃnity precipitates, detect
a band in the nuclear extracts, but not in the RNA aﬃnity precipitates.
Nucleic Acids Research, 2007, Vol. 35, No. 12 4171Changes in hnRNPs expression are associated with the
developmental switch in the endogenous PLP/DM20
ratio. The PLP/DM20 ratio was 3:1 in OLs compared
with 1.5:1 in OPC (n=3) (Figure 7A) and replicates the
developmental increase in PLP/DM20 ratio in the post-
natal brain (32). The data show a temporal association
between decrease in hnRNPs expression levels and
increase in the PLP/DM20 ratio.
We next assessed whether changes in the expression of
hnRNPs in diﬀerentiated versus undiﬀerentiated Oli-neu
cells replicate the pattern observed in primary OLs.
Oli-neu cells were either grown in serum-containing
medium or diﬀerentiated for 3, 7 and 10 days in
dbcAMP-containing medium. Oli-neu cells reach a
higher degree of diﬀerentiation after 7 and 10 days of
culture in dbcAMP-containing medium (21). Signiﬁcant
reductions in hnRNP F and A1, but only modest
decreases in hnRNPH were detected in Oli-neu diﬀer-
entiated for 7 and 10 days compared with undiﬀerentiated
and 3 day-diﬀerentiated Oli-neu cells (Figure 7C). CNPase
expression was used as an internal marker of diﬀerentia-
tion (Figure 7C). These results demonstrate that changes
in hnRNPs associated with diﬀerentiation of Oli-neu cells
generally replicate the results obtained with OLs.
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Figure 7. The hnRNPs expression in primary OLs and Oli-neu cells. (A) Representative RT-PCR products of the endogenous PLP and
DM20 transcripts in RNA isolated from OPC and OLs diﬀerentiated for 72h. The bar graph represents the mean SD (n=3). (B) Representative
Western blot of nuclear extracts prepared from OPC and OLs diﬀerentiated for 72h and probed with antibodies speciﬁc for hnRNPA1, H, F and L
(see Materials and Methods section). CNPase expression was assessed in cytoplasmic extracts. Tubulin is a control for loading accuracy. The data
were reproduced in ﬁve separate primary OLs preparations. Bands were quantiﬁed by densitometry and the value was corrected by the internal
control tubulin. The bar graph represents the percent expression SD of each protein in OLs nuclear extracts relative to the level detected in OPC
nuclear extracts, which is set at 100 (n=5). Reduction of H (P=0.006), F (P=0.003) and A1 (P=0.02) in diﬀerentiated OLs versus OPC were all
signiﬁcant. (C) Representative Western blot of nuclear extracts prepared from undiﬀerentiated Oli-neu cells (growth) and diﬀerentiated for 3, 7 and
10 days and probed with antibodies speciﬁc for hnRNPA1, H, F and L. Tubulin is control for loading accuracy. The data were reproduced in three
separate experiments. Bands were quantiﬁed by densitometry and the values were corrected by the internal control tubulin. CNPase expression was
assessed in cytoplasmic extracts. The bar graph represents the percent expression SD of each protein in the Oli-neu nuclear extracts relative to the
level detected in undiﬀerentiated cells, which is set at 100 (n=3). The reduction of F and A1 expression in diﬀerentiated Oli-neu cells was signiﬁcant
at 7 and 10 days versus undiﬀerentiated Oli-neu cells (P=0.0017 for F and P=0.001 for A1). The decrease of H in diﬀerentiated Oli-neu cells
versus undiﬀerentiated Oli-neu cells did not reach statistical signiﬁcance. Levels of hnRNPL did not change.
4172 Nucleic Acids Research, 2007, Vol. 35, No. 12Together, the data show that a decrease in hnRNP H,
F and A1 expression occurs in diﬀerentiated OLs and is
temporally associated with diﬀerentiation-dependent
increase in PLP/DM20 ratio in OLs.
Knock down of hnRNPH and Fincreases the PLP/DM20
ratio inundifferentiated OLs
The coordinate decrease in the expression of hnRNP H, F
and A1 in OLs suggests that these splicing factors may
regulate the changes in the PLP/DM20 ratio. We have
tested whether RNAi-mediated removal of either
hnRNPH or F is suﬃcient to increase the PLP/DM20
ratio in undiﬀerentiated Oli-neu cells in which the
endogenous expression of H and F is high. Oli-neu cells
were treated with siRNA that either target hnRNPH
(siH1, H2, H3) or hnRNPF (siF1, F2 and F3) (Ambion,
see Materials and Methods section) and hnRNPH and
F levels were quantiﬁed by Western blot of cell lysates
prepared 72h after transfection. hnRNPH was reduced by
70% with siH2, 50% with siH3 and 40% with siH1
(Figure 8A). hnRNPF was reduced by 60% with siF2
and 40% with siF3, while was unaﬀected by siF1
(Figure 8A). Expression of hnRNP A1 and L was not
changed by treatment with the siRNAs, conﬁrming the
speciﬁcity of the knock down (data not shown).
Subsequent experiments were carried out with siH3, H1
and siF2, F3.
To determine whether knock down of either hnRNPF
or H aﬀects the PLP/DM20 ratio, we transfected PLP-neo
and siRNAs into Oli-neu cells. The plasmid-derived PCR
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Figure 8. RNAi-mediated knock down of hnRNPH and F increases the PLP/DM20 ratio in Oli-neu cells. (A) Representative Western blot of
cell extracts prepared from Oli-neu cells treated with siRNAs that target hnRNPH (siH1, H2, H3), hnRNPF (siF1, F2 and F3) and both H and F
(siF/H). Mock are cells treated with negative control siRNA. After quantiﬁcation of the bands, the values were corrected by actin, used as control for
loading accuracy. The hnRNPH was reduced by 40, 70 and 50% in cells treated with siH1, siH2 and siH3 and 50% in cells treated with siH/F versus
control (n=2). The hnRNPF was reduced by 60 and 40% in cells treated with siF2 and siF3 and by 60% in cells treated with siF/H versus controls.
(B) Representative RT-PCR analysis of the PLP-neo derived PLP and DM20 spliced products and the endogenous PLP and DM20 transcripts
ampliﬁed from RNA isolated from Oli-neu cells treated with siH1, siH3, siF2, siF3, siF3+H3 and siF/H (35 PCR cycles). The bar graph shows
the PLP/DM20 ratios SD (n=3). Mock are cells treated with control siRNA. Increase in PLP/DM20 ratio is statistically signiﬁcant for siH3
(P50.05) and for siF3+H3 and siF/H (P50.01)-treated cells compared with mock-treated cells.
Nucleic Acids Research, 2007, Vol. 35, No. 12 4173products were ampliﬁed in RNA prepared from trans-
fected Oli-neu cells cultured for 72h in growth medium
(Figure 8B). Knock down of hnRNPH resulted in42-fold
increase in the PLP/DM20 ratio in cells treated with siH3
compared with mock treated cells (0.98 versus 0.36)
(similar results were obtained with H2, data not shown),
a smaller increase was induced by siH1 (0.56 versus 0.36),
consistent with lower silencing eﬃcacy of siH1 on
hnRNPH expression (Figure 8B, upper panel). The PLP/
DM20 ratio was not increased by treatment with siF2 and
siF3, although the levels of hnRNPF are signiﬁcantly
reduced by the treatment (Figure 8B, upper panel). These
data show that reduction in hnRNPH is suﬃcient to
increase the PLP/DM20 ratio, while knock down of
hnRNPF does not have an eﬀect on the PLP/DM20 ratio.
To determine whether knock down of both hnRNP H
and F cooperatively regulates the PLP/DM20 ratio, we
co-transfected Oli-neu cells with siF3+siH3 and PLP-neo.
The simultaneous knock down of hnRNPF and H caused
10-fold increase in the PLP/DM20 ratio compared
with mock treated cells (3.5 versus 0.36) (Figure 8B).
siF2 combined with either siH2 or siH3 treatments gave
similar results (data not shown). The data suggest that
hnRNPH and F cooperatively regulate PLP/DM20 ratio
and their knock down results in a synergistic eﬀect. These
ﬁndings were conﬁrmed by knock down of hnRNPH and
F with a custom-made siRNA that targets both hnRNPF
and H (siF/H) (Ambion, see Methods and Materials
section). siF/H reduced the expression of hnRNPF
by 60% and hnRNPH by 50% (Figure 8A) and caused
a 10-fold increase in the PLP/DM20 ratio (Figure 8B,
upper panel).
We have also determined that knock down of
hnRNPH and hnRNPH+F increased exon 3B inclusion
in GloPLP-derived products similarly to PLP-neo
(data not shown), suggesting that exon 3B and intron 3
contain regulatory elements that mediate the eﬀects of
hnRNPH and F. We next evaluated whether knock down
of hnRNPH and F increases the endogenous PLP/DM20
ratio. Knock down of both hnRNPH and F caused 2-fold
increase in the endogenous PLP/DM20 ratio compared
with mock treated cells (1 versus 0.5), while removal of
hnRNPH increased the PLP/DM20 ratio modestly
(0.8 versus 0.5) (Figure 8B, lower panel). These results
demonstrate a role of hnRNPH and F in the regulation
of the endogenous and plasmid-derived PLP alternative
splicing.
Because hnRNPH and F bind to M2 and ISE, we tested
whether the presence of M2 and ISE is required for the
hnRNPH and F-mediated eﬀect on PLP/DM20 ratio.
If either M2 or ISE is necessary for hnRNPH and F
transactivation, mutation of these enhancers would
reduce the increase in the PLP/DM20 ratio induced by
removal of hnRNPH and F. Knock down of hnRNPH did
not change the PLP/DM20 ratio derived from M2-MT
compared with mock treated cells, while knock down of
both hnRNPH and F caused 53-fold increase in PLP/
DM20 ratio (5.5 versus 2), which is much lower than the
10-fold increase in PLP/DM20 ratio derived from the WT
(Figure 9A). Although the PLP/DM20 ratio derived from
M2-MT is relatively high (2), the smaller increase in PLP/
DM20 ratio is not due to limitation in detection and
quantiﬁcation of the PCR products, as we can accurately
quantify PLP/DM20 ratio of up to 10 (Figure 3).
The PLP/DM20 ratio derived from the ISEdel was
increased 3-fold by removal of hnRNPH (0.37 versus 0.13)
(Figure 9B). Knock down of hnRNPH and F with
siF3+siH3 increased the PLP/DM20 ratio 7-fold (0.93
versus 0.13) and with siF/H increased the ratio 10-fold
(1.32 versus 0.13) (Figure 9B). Although the eﬃciency of
PLP 50 splice site selection is low in the ISEdel, the fold
increase in the PLP/DM20 ratio induced by knock down
of hnRNPH and hnRNPH+F is similar to that derived
from the PLP-neo. When both M2 and ISE are mutated
(M2-MT/ISEdel) knock down of hnRNPH did not
change the PLP/DM20 ratio (Figure 9C) similar to the
results obtained with M2-MT (Figure 9A). The PLP/
DM20 ratio derived from M2-MT/ISEdel was increased
42-fold by treatment with siF3+siH3 (1.43 versus 0.6)
and43-fold by siH/F (2.13 versus 0.6) (Figure 9C) similar
to the results obtained with M2-MT (Figure 9A). These
data suggest that disabling M2 interferes with hnRNPH-
mediated eﬀect on the PLP/DM20 and greatly reduces,
although does not completely eliminate the synergistic
eﬀect induced by removal of hnRNPH and F. The latter
result suggests that sequences other than M2 and ISE and
contained in PLP exon 3B and intron 3, also participate in
mediating the synergistic eﬀect.
We next determined whether the other G-rich sequences
present in exon 3B may mediate the increase in PLP/
DM20 ratio derived from M2-MT/ISEdel after knock
down of hnRNPH and F. We have replaced G runs in
M1 (G1), M6 (G4) and M8 (G5) with T’s in the
M2-MT/ISEdel (Figure 10A) and determined the PLP/
DM20 ratio derived from this construct in transfected
Oli-neu cells (Figure 10B). The PLP/DM20 ratio derived
from M2-MT/ISEdel/G1-G4-G5-MT was 0.22 which
is similar to the ratio derived from the WT (Figure 2A).
The PLP/DM20 ratio derived from M2-MT/ISEdel-G1-
G4-G5MT in Oli-neu cells treated with siF3+siH3 did
not change compared with mock treated cells (0.27 versus
0.22), while  1.6-fold increase was detected after
treatment with siF/H (0.4 versus 0.22) (Figure 10B).
The data show that mutations of G1, G4 and G5 in
addition to M2 almost completely abolish the PLP/DM20
increase induced by knock down of hnRNPH/F and
suggest that some or all of these G runs participate in
mediating the synergistic eﬀect.
DISCUSSION
Regulation of PLP alternative splicing and maintenance
of the PLP/DM20 ratio are critical for brain function and
are relevant to neurological disorders in humans (15).
In this study, we have identiﬁed a novel G-rich enhancer
(M2) of DM20 50 splice site selection and show that it is
active in OLs and non-glial cells. However, the overall
eﬃciency of PLP alternative splicing and the impact
that mutation of M2 has on the PLP/DM20 ratio is
dependent on cell-speciﬁc (compare Oli-neu with L cells)
4174 Nucleic Acids Research, 2007, Vol. 35, No. 12and diﬀerentiation-dependent factors (compare OLs
versus Oli-neu).
The presence of M2 and ISE downstream of DM20 and
PLP 50 splice sites suggests that the PLP/DM20 ratio
may be regulated by a balance between these enhancers.
We have addressed this question both functionally and
biochemically. When switched, M2 and ISE diﬀer in the
strength with which they enhance the upstream 50 splice
site. Changes in the distance of the G-rich sequences
from the 50 splice site in the switched position and the
presence of putative ESE in the exonic context and their
potential interaction with the G-rich enhancer may
account for the diﬀerence in strength. However, we
favor the hypothesis that sequences immediately adjacent
to the G runs may inﬂuence the enhancer’s strength. In the
ISE, the ﬂanking sequences enhance the PLP 50 site
selection (15), while sequences adjacent to M2 reduce the
DM20 50 splice site selection (Figure 2, M1-MT and
M3-MT). In addition, the biochemical studies show that
some proteins exclusively bind to either M2 or ISE and
mutations of the G-rich sequences have a diﬀerent impact
on the binding of proteins to M2F and ISE. Together,
these data would support the interpretation that sequence-
dependent diﬀerences in protein binding may play a role in
deﬁning the function of M2 and ISE. Identiﬁcation and
characterization of these proteins in future studies will
allow to test this hypothesis.
In this report, we show that the G runs are necessary for
binding of hnRNPs to both enhancers. Potential binding
motifs for hnRNPH and F are poly G sequences in M2
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Figure 9. The eﬀect of mutation of M2 and ISE on the hnRNPH and F-mediated regulation of PLP/DM20. (A) Representative RT-PCR analysis of
the M2-MT derived PLP and DM20 products ampliﬁed from RNA isolated from Oli-neu cells treated with siH3, siF3, siF3+H3, siF/H (35 PCR
cycles). Mock are cells treated with control siRNA. The bar graph shows the PLP/DM20 ratios SD (n=3). The increase in PLP/DM20 ratio
induced by siF3+H3 and siF/H are statistically signiﬁcant (P50.01). (B) Representative RT-PCR analysis of the ISEdel derived PLP and DM20
products ampliﬁed from RNA prepared from Oli-neu cells treated with siH3, siF3, siF3+H3, siF/H (35 PCR cycles). Mock are cells treated with
control siRNA. The bar graph shows the PLP/DM20 ratios SD (n=3). The increase in PLP/DM20 ratio induced by siH3, siF3+H3 and siF/H is
statistically signiﬁcant (P50.01). (C) Representative RT-PCR analysis of the M2-MT/ISEdel derived PLP and DM20 products ampliﬁed from RNA
prepared from Oli-neu cells treated with siH3, siF3, siF3+H3, siF/H (35 PCR cycles). Mock are cells treated with control siRNA. The bar graph
shows the PLP/DM20 ratios SD (n=3). The changes in PLP/DM20 ratio induced by siF3+H3 and siF/H are statistically signiﬁcant (P50.05).
Nucleic Acids Research, 2007, Vol. 35, No. 12 4175and ISE (29,33) while hnRNPA1 may bind to a partial
consensus sequence -AGGG- (Figure 6) (34) present in
single copy in ISE and in double copy in M2. An
unexpected ﬁnding is that hnRNPL binds to M2 and ISE,
since the high aﬃnity site for L is not present in M2 and
ISE (35,36) and only partial motifs, CCA in M2F and
ACA in the ISE are found. It is possible that hnRNPL
does not bind directly to M2 and ISE, but is a part of a
molecular complex formed by sequence-speciﬁc binding of
hnRNPH, F and A1 to these enhancers.
Unlike previous ﬁndings that the G triplet is the basic
functional unit of G-rich enhancers (28), in M2 the 30 G
triplet exerts a dominant enhancing eﬀect, while the bases
separating the G triplets reduce DM20 50 splice site
selection. The functional complexity of M2 may modulate
the overall strength of the enhancer in response to changes
in RNA-binding proteins during OLs diﬀerentiation.
The developmental decrease in hnRNPF, H and A1 in
diﬀerentiated OLs would support the hypothesis. The
hnRNPs are diﬀerentially expressed in various tissues (37)
and hnRNPH is linked to diﬀerentiation of muscle cells
(38), however, to our knowledge, coordinate decrease in
hnRNPH, F and A1 associated with diﬀerentiation was
not previously reported.
Removal of both hnRNPH and F has uncovered a
novel synergistic eﬀect on PLP alternative splicing
regulation mediated by hnRNPH and F, and points to a
critical role of hnRNPH in this process. The hnRNPH is
suﬃcient to aﬀect the PLP/DM20 ratio and is necessary
for hnRNPF to aﬀect the PLP/DM20 ratio. Although
knock down of both hnRNPH and F reduces the shorter
of the two products derived by alternative splicing of
competing 50 splice sites in the bclx gene more strongly
than knock down of either hnRNPH or F alone, a
synergistic eﬀect was not identiﬁed in these studies (18).
The broader signiﬁcance of hnRNPH and F synergistic
eﬀect in regulating alternative 50 splice site selection of
other genes remains to be investigated. Our ﬁndings
raise important questions as to whether the synergism
of hnRNPF and H is cell-speciﬁc and limited to OLs
or represents a more general way of regulating
50 alternative splicing and whether the synergism is gene
context speciﬁc.
We have started to investigate cis-acting elements that
may participate in the hnRNP’s mediated regulation
and have assessed whether M2 and ISE are necessary
for hnRNPH and F to aﬀect the PLP/DM20 ratio. The
presence of M2 appears to be required for the eﬀect of
hnRNPH, since removal of hnRNPH does not increase
the PLP/DM20 ratio when M2 is mutated. In contrast,
the synergistic eﬀect of hnRNPH+F knock down
depends only in part on the presence of M2, since
mutation of M2 either alone or in combination with
ISEdel greatly reduces the fold increase in the PLP/DM20
ratio, but does not completely abolish it. However, when
the other G runs in exon 3B are mutated the synergistic
eﬀect is almost completely eliminated. We interpret these
results to indicate that M2 in part contributes to the eﬀect
of hnRNPH+F on the PLP/DM20 ratio and that G runs
in exon 3 B sequences other than M2 and ISE also play a
role. The ﬁnding that replacement of G runs in diﬀerent
positions in exon 3B aﬀects the hnRNPH/F-mediated
regulation of PLP/DM20 ratio corroborates the data
obtained with the M1–M10 substitutions and support
that multiple regulatory sequences are present in PLP
exon 3B. The role and relative contribution of each G run
to the synergistic eﬀect remain to be elucidated.
How M2 may participate in hnRNPH- and
F-dependent regulation of PLP alternative splicing
remains to be determined. Our data do not demonstrate
that hnRNPH and F act directly through M2. For
instance, M2 may enhance DM20 50 splice site selection
through a mechanism that is independent from hnRNPH
and F such as formation of stacked G structures (39).
Figure 10. The eﬀect of mutation of G1, G4 and G5 on the hnRNPH and F-mediated regulation of PLP/DM20. (A) Partial sequences of PLP exon
3B/intron 3 (WT) and of mutations of M2/ISE and G1, G4 and G5 in exon 3B (M2-MT/ISEdel-G1-G4-G5MT) are shown. (B) Representative
RT-PCR analysis of the M2-MT/ISEdel-G1-G4-G5MT derived PLP and DM20 products ampliﬁed from RNA isolated from Oli-neu cells treated
with siF3+H3, siF/H (35 PCR cycles). Mock are cells transfected with M2-MT/ISEdel-G1-G4-G5MT and treated with control siRNA. The bar
graph shows the PLP/DM20 ratios SD (n=3).
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50 splice site recognition reducing the eﬃciency of splicing
rather than aﬀecting hnRNPH- and F-mediated trans-
activation directly. Alternatively, loss of G stacked
structure may indirectly reduce the eﬃciency of
hnRNPH and F binding to other cognate sequences.
Our data suggest that ISE does not participate in the
hnRNPF- and H-dependent regulation of the PLP/DM20
ratio at least in undiﬀerentiated OLs. However, it is
possible that a role of ISE is overlooked in our studies if
reduction of hnRNPH and F needs to be coupled to
diﬀerentiation-induced changes in other cell-speciﬁc and
ubiquitous trans-acting splicing factors (40,41).
In summary, our studies have identiﬁed a novel
G-rich enhancer and a synergistic eﬀect of hnRNPF
and H in regulating the PLP/DM20 ratio and suggest
that these splicing factors, the G-rich enhancer and
other G runs may together regulate PLP/DM20 ratio
in OLs. Elucidation of the mechanism that mediates
the synergistic interactions of hnRNPH and F may reveal
a novel role of these splicing factors in 50 alternative
splicing.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.
ACKNOWLEDGEMENTS
The authors thank Dr Martha Peterson for helpful
discussion and critical reading of the manuscript,
Dr Doug Black for critical reading of the manuscript
and helpful suggestions, Dr Milcarek for hnRNPF and H
antibodies, Dr Dreyfuss for hnRNPA1 antibody and
Dr Black for the DUP4-1 construct. This work was
supported in part by the European Leukodystrophy
Association and by NIH/NINDS (RO1NS053905).
Funding to pay the Open Access publication charges for
this article was provided by NIH/NINDS
(RO1NS053905) and European Leukodystrophy
Association (ELA Fondation).
Conﬂict of interest statement. None declared.
REFERENCES
1. Modrek,B. and Lee,C.J. (2003) Alternative splicing in the human,
mouse and rat genomes is associated with an increased frequency of
exon creation and/or loss. Nat. Genet., 34, 177–180.
2. Sugnet,C.W., Kent,W.J., Ares,M. Jr. and Haussler,D. (2004)
Transcriptome and genome conservation of alternative splicing
events in humans and mice. Pac. Symp. Biocomput., 66–77.
3. Matlin,A.J., Clark,F. and Smith,C.W. (2005) Understanding
alternative splicing: towards a cellular code. Nat. Rev. Mol.
Cell Biol., 6, 386–398.
4. Wang,Z., Xiao,X., Van Nostrand,E. and Burge,C.B. (2006) General
and speciﬁc functions of exonic splicing silencers in splicing control.
Mol. Cell, 23, 61–70.
5. Black,D.L. and Grabowski,P.J. (2003) Alternative pre-mRNA
splicing and neuronal function. Prog. Mol. Subcell. Biol., 31,
187–216.
6. Grabowski,P.J. and Black,D.L. (2001) Alternative RNA splicing in
the nervous system. Prog. Neurobiol., 65, 289–308.
7. Nave,K.A., Lai,C., Bloom,F.E. and Milner,R.J. (1987) Splice site
selection in the proteolipid protein (PLP) gene transcript and
primary structure of the DM-20 protein of central nervous system
myelin. Proc. Natl Acad. Sci. USA, 84, 5665–5669.
8. Campagnoni,A.T. and Macklin,W.B. (1988) Cellular and molecular
aspects of myelin protein gene expression. Mol. Neurobiol., 2, 41–89.
9. Timsit,S.G., Bally-Cuif,L., Colman,D.R. and Zalc,B. (1992) DM-20
mRNA is expressed during the embryonic development of the
nervous system of the mouse. ([A-Z]). J. Neurochem., 58,
1172–1175.
10. Venkatesh,B., Erdmann,M.V. and Brenner,S. (2001) Molecular
synapomorphies resolve evolutionary relationships of extant jawed
vertebrates. Proc. Natl Acad. Sci. USA, 98, 11382–11387.
11. Yoshida,M. and Colman,D.R. (1996) Parallel evolution and
coexpression of the proteolipid proteins and protein zero in
vertebrate myelin. Neuron, 16, 1115–1126.
12. Gudz,T.I., Schneider,T.E., Haas,T.A. and Macklin,W.B. (2002)
Myelin proteolipid protein forms a complex with integrins and may
participate in integrin receptor signaling in oligodendrocytes.
J. Neurosci., 22, 7398–7407.
13. Stecca,B., Southwood,C.M., Gragerov,A., Kelley,K.A.,
Friedrich,V.L. Jr. and Gow,A. (2000) The evolution of lipophilin
genes from invertebrates to tetrapods: DM-20 cannot replace
proteolipid protein in CNS myelin. J. Neurosci., 20, 4002–4010.
14. Hobson,G.M., Huang,Z., Sperle,K., Sistermans,E., Rogan,P.K.,
Garbern,J.Y., Kolodny,E., Naidu,S. and Cambi,F. (2006) Splice-site
contribution in alternative splicing of PLP1 and DM20: molecular
studies in oligodendrocytes. Hum. Mutat., 27, 69–77.
15. Hobson,G.M., Huang,Z., Sperle,K., Stabley,D.L., Marks,H.G. and
Cambi,F. (2002) A PLP splicing abnormality is associated with an
unusual presentation of PMD. Ann. Neurol., 52, 477–488.
16. Wang,E., Huang,Z., Hobson,G.M., Dimova,N., Sperle,K.,
McCullough,A. and Cambi,F. (2006) PLP1 alternative splicing in
diﬀerentiating oligodendrocytes: characterization of an exonic
splicing enhancer. J. Cell Biochem., 97, 999–1016.
17. Elrick,L.L., Humphrey,M.B., Cooper,T.A. and Berget,S.M. (1998)
A short sequence within two purine-rich enhancers determines
50 splice site speciﬁcity. Mol. Cell Biol., 18, 343–352.
18. Garneau,D., Revil,T., Fisette,J.F. and Chabot,B. (2005)
Heterogeneous nuclear ribonucleoprotein F/H proteins modulate
the alternative splicing of the apoptotic mediator Bcl-x. J. Biol.
Chem., 280, 22641–22650.
19. Humphrey,M.B., Bryan,J., Cooper,T.A. and Berget,S.M. (1995)
A 32-nucleotide exon-splicing enhancer regulates usage of
competing 50 splice sites in a diﬀerential internal exon.
Mol. Cell Biol., 15, 3979–3988.
20. Huang,Z., Tang,X.M. and Cambi,F. (2002) Down-regulation of the
retinoblastoma protein (rb) is associated with rat oligodendrocyte
diﬀerentiation. Mol. Cell Neurosci., 19, 250–262.
21. Jung,M., Kramer,E., Grzenkowski,M., Tang,K., Blakemore,W.,
Aguzzi,A., Khazaie,K., Chlichlia,K., von Blankenfeld,G. et al.
(1995) Lines of murine oligodendroglial precursor cells immortal-
ized by an activated neu tyrosine kinase show distinct degrees of
interaction with axons in vitro and in vivo. Eur. J. Neurosci., 7,
1245–1265.
22. Alkan,S.A., Martincic,K. and Milcarek,C. (2006) The hnRNPs F
and H2 bind to similar sequences to inﬂuence gene expression.
Biochem. J., 393, 361–371.
23. Veraldi,K.L., Arhin,G.K., Martincic,K., Chung-Ganster,L.H.,
Wilusz,J. and Milcarek,C. (2001) hnRNP F inﬂuences binding of a
64-kilodalton subunit of cleavage stimulation factor to mRNA
precursors in mouse B cells. Mol. Cell Biol., 21, 1228–1238.
24. Simons,M., Kramer,E.M., Macchi,P., Rathke-Hartlieb,S.,
Trotter,J., Nave,K.A. and Schulz,J.B. (2002) Overexpression of the
myelin proteolipid protein leads to accumulation of cholesterol and
proteolipid protein in endosomes/lysosomes: implications for
Pelizaeus-Merzbacher disease. J. Cell Biol., 157, 327–336.
25. Yang,G., Huang,S.C., Wu,J.Y. and Benz,E.J. (2005) An erythroid
diﬀerentiation-speciﬁc splicing switch in protein 4.1R mediated by
the interaction of SF2/ASF with an exonic splicing enhancer. Blood,
105, 2146–2153.
26. Nalla,V.K. and Rogan,P.K. (2005) Automated splicing mutation
analysis by information theory. Hum. Mutat., 25, 334–342.
Nucleic Acids Research, 2007, Vol. 35, No. 12 417727. Lynch,K.W. and Weiss,A. (2001) A CD45 polymorphism associated
with multiple sclerosis disrupts an exonic splicing silencer. J. Biol.
Chem., 276, 24341–24347.
28. McCullough,A.J. and Berget,S.M. (1997) G triplets located through-
out a class of small vertebrate introns enforce intron borders and
regulate splice site selection. Mol. Cell Biol., 17, 4562–4571.
29. Caputi,M. and Zahler,A.M. (2001) Determination of the RNA
binding speciﬁcity of the heterogeneous nuclear ribonucleoprotein
(hnRNP) H/H’/F/2H9 family. J. Biol. Chem., 276, 43850–43859.
30. Grabowski,P.J. (2004) A molecular code for splicing silencing:
conﬁgurations of guanosine-rich motifs. Biochem. Soc. Trans., 32,
924–927.
31. Galarneau,A. and Richard,S. (2005) Target RNA motif and target
mRNAs of the Quaking STAR protein. Nat. Struct. Mol. Biol., 12,
691–698.
32. Sporkel,O., Uschkureit,T., Bussow,H. and Stoﬀel,W. (2002)
Oligodendrocytes expressing exclusively the DM20 isoform of the
proteolipid protein gene: myelination and development. GLIA, 37,
19–30.
33. Matunis,M.J., Xing,J. and Dreyfuss,G. (1994) The hnRNP F
protein: unique primary structure, nucleic acid-binding properties,
and subcellular localization. Nucleic Acids Res., 22, 1059–1067.
34. Blanchette,M. and Chabot,B. (1999) Modulation of exon skipping
by high-aﬃnity hnRNP A1-binding sites and by intron elements
that repress splice site utilization. EMBO J., 18, 1939–1952.
35. Hui,J., Hung,L.H., Heiner,M., Schreiner,S., Neumuller,N.,
Reither,G., Haas,S.A. and Bindereif,A. (2005) Intronic CA-repeat
and CA-rich elements: a new class of regulators of mammalian
alternative splicing. EMBO J., 24, 1988–1998.
36. Hui,J., Stangl,K., Lane,W.S. and Bindereif,A. (2003) HnRNP L
stimulates splicing of the eNOS gene by binding to variable-length
CA repeats. Nat. Struct. Biol., 10, 33–37.
37. Kamma,H., Portman,D.S. and Dreyfuss,G. (1995) Cell type-speciﬁc
expression of hnRNP proteins. Exp. Cell Res., 221, 187–196.
38. Liu,J., Beqaj,S., Yang,Y., Honore,B. and Schuger,L. (2001)
Heterogeneous nuclear ribonucleoprotein-H plays a suppressive role
in visceral myogenesis. Mech. Dev., 104, 79–87.
39. Kostadinov,R., Malhotra,N., Viotti,M., Shine,R., D’Antonio,L.
and Bagga,P. (2006) GRSDB: a database of quadruplex forming
G-rich sequences in alternatively processed mammalian pre-mRNA
sequences. Nucleic Acids Res., 34, D119–D124.
40. Chou,M.Y., Rooke,N., Turck,C.W. and Black,D.L. (1999)
hnRNP H is a component of a splicing enhancer complex that
activates a c-src alternative exon in neuronal cells. Mol. Cell Biol.,
19, 69–77.
41. Markovtsov,V., Nikolic,J.M., Goldman,J.A., Turck,C.W.,
Chou,M.Y. and Black,D.L. (2000) Cooperative assembly of
an hnRNP complex induced by a tissue-speciﬁc homolog of
polypyrimidine tract binding protein. Mol. Cell Biol., 20,
7463–7479.
4178 Nucleic Acids Research, 2007, Vol. 35, No. 12